| abstract |
The present invention provides a method for diagnosing, treating, and treating cancer (e.g., renal cancer (e.g., renal cell carcinoma (RCC)). The present invention provides a method for treating cancer in a sample obtained from an individual suffering from cancer. The expression level of one or more biomarkers described herein in a VEGF antagonist (eg, an anti-VEGF antibody (eg, bevacizumab) or a VEGFR inhibitor (eg, a multitargeted tyrosine kinase inhibitor ( (e.g., sunitinib, axitinib, pazopanib, or caboxantinib)) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1) with an antibody, such as atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (eg, an anti-PD-1 antibody)), or an angiogenesis inhibitor (eg, a VEGF antagonist (eg, In a method for predicting the therapeutic efficacy of treatment with a VEGFR inhibitor (eg, a multitargeted tyrosine kinase inhibitor (eg, sunitinib, axitinib, pazopanib, or caboxantinib))) It is based, at least in part, on the discovery that it can be used. |